HSP90 Expression: A New Predictive Factor for BCG Response in Stage Ta-T1 Grade 3 Bladder Tumours
| Autor: | R. William G. Watson, John M. Fitzpatrick, Thierry Lebret, Amanda O'Neill, Jean-Eudes Poulain, Vincent Molinié, Henry Botto |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Nephrology
medicine.medical_specialty Pathology Urology medicine.medical_treatment Cystectomy complex mixtures Gastroenterology Adjuvants Immunologic Heat shock protein Internal medicine Immunochemistry Biomarkers Tumor medicine Humans Neoplasm HSP90 Heat-Shock Proteins Stage (cooking) Carcinoma Transitional Cell Bladder cancer business.industry Prognosis medicine.disease Immunohistochemistry Treatment Outcome Urinary Bladder Neoplasms BCG Vaccine HSP60 Neoplasm Recurrence Local business Adjuvant |
| Zdroj: | European Urology. 51:161-167 |
| ISSN: | 0302-2838 |
| DOI: | 10.1016/j.eururo.2006.06.006 |
| Popis: | Although Bacillus Calmette-Guérin (BCG) instillations are considered as the adjuvant treatment of choice for stage Ta-T1 grade G3 bladder tumours, there is no consensus for a predictive factor to assess BCG success. This study attempted to evaluate if heat shock proteins (HSPs) could be useful predictive markers in BCG responses.Thirty-three primary resected G3 superficial bladder tumours were included in the study. All patients received adjuvant BCG instillations. The mean follow-up was 56 mo (range: 24-132 mo). HSP expression was evaluated by immunochemistry.In the 33 patients, 18 had no recurrence (group 1), 9 had recurrence with no muscular invasion (group 2), and 6 had an invasive recurrence (group 3). A significant correlation was found between lack of expression of HSP90 and BCG response: the mean HSP expression was 92.7%, 84.4%, and 26.7% for groups 1, 2 and 3 tumours, respectively (p0.0001). For the 6 patients who did not positively respond to BCG, HSP expression was40%. All the tumours with a HSP90 expression40% positively responded to BCG, corresponding to group 1 or 2 patients. In contrast, HSP60 expression was not correlated to the BCG response.HSP90 could be considered as a very promising marker to assess BCG treatment response. Low HSP90 expression (40%) could be useful to predict BCG failure and early stage cystectomy could be proposed for these selected patients with primary high-risk grade 3 superficial bladder tumours. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect